Call Options

10 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $293,862 - $370,242
20,100 Added 186.11%
30,900 $502,000
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $188,574 - $327,116
10,600 Added 5300.0%
10,800 $199,000
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $87,276 - $133,434
-4,200 Reduced 95.45%
200 $6,000
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $91,696 - $147,268
4,400 New
4,400 $91,000
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $56,800 - $74,520
-4,000 Reduced 39.6%
6,100 $97,000
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $142,511 - $184,527
10,100 New
10,100 $165,000
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $699,465 - $1.04 Million
-22,100 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $644,538 - $914,920
17,800 Added 413.95%
22,100 $945,000
Q3 2019

Nov 14, 2019

SELL
$22.22 - $44.01 $713,262 - $1.41 Million
-32,100 Reduced 88.19%
4,300 $155,000
Q2 2019

Aug 14, 2019

BUY
$23.32 - $28.12 $848,848 - $1.02 Million
36,400 New
36,400 $973,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.